Update on progress of Phase I/IIa Clinical Trial (5378B)
February 21 2011 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 5378B
Immupharma PLC
21 February 2011
For Immediate Release 21 February 2011
ImmuPharma plc
Update on progress of Phase I/IIa Clinical Trial with
IPP-204106: Cancer patients stabilised with ImmuPharma's Cancer
Compound
ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the
"Group"), the specialist discovery and development pharmaceutical
company is pleased to announce encouraging results from its ongoing
phase I/IIa clinical trial in cancer patients:
Key Highlights:
-- Around half of the cancer patients that have undergone
treatment with ImmuPharma's drug candidate IPP-204106 are in stable
condition (their disease has stopped progressing) without any other
drug treatment. All the patients that enrolled in the study were
suffering from advanced cancer with metastases and had all failed
their previous treatments with other existing cancer drugs.
-- The third dose level of IPP-204106 has just begun in the next
group of patients. ImmuPharma's clinical trial began last summer
and up to now two lower dose levels have been tested. The initial
dose level of 1 mg/kg did not show any drug-related side effects.
The first patient to be treated in this study is still alive and
with stable disease 8 months after starting treatment with
ImmuPharma's cancer compound. The second dose level of 2 mg/kg also
did not show any drug-related side effects.
-- ImmuPharma has already begun development of the next
generation of IPP-204106, the "micro Nucants". This improved
formulation comprising of small particles of the drug candidate has
shown an even more impressive efficacy in cancer models.
The clinical trial is taking place in two hospitals in Paris and
one hospital in Dijon, in France and is expected to complete in the
coming months. Further details and analysis will be provided at the
end of the study.
ImmuPharma hopes to start a Phase IIb programme later this year
in patients with glioblastoma (brain tumour), hormone-resistant
prostate cancer and pancreatic cancer.
Dr Robert Zimmer, MD, PhD, ImmuPharma's President and Chief
Scientific Officer commented: "It is indeed a pleasure and an
honour to see cancer patients benefiting from our new drug
candidate in our clinical trial. Seeing that the first patient that
started treatment with IPP-204106 is still alive and in a stable
condition after eight months of treatment gives us confidence in
our programme. The improved formulation is a great achievement and
further strengthens our position in this field."
Dimitri Dimitriou, MSc, ImmuPharma's Chief Executive Officer
added: "Having now two drug candidates with positive results in
clinical trials is a milestone for ImmuPharma. The latest positive
results of our cancer drug candidate clinical trial puts our
Company in a good position for further major corporate deals such
as the one with our partner Cephalon on Lupuzor(TM) that is now in
a large late-stage clinical trial in the United States. This also
marks the fifth anniversary of ImmuPharma's admission to trading on
AIM. With our strong cash position and pipeline, we are excited to
continue our success.
For further information, please contact:
ImmuPharma PLC:
Dr Robert Zimmer, President & Chief Scientific Officer + 33
389 32 76 50
Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080
Richard Warr, Chairman +44 20 7152 4080
Buchanan Communications
Lisa Baderoon, Mark Court, Jessica Fontaine +44 20 7466 5000
Panmure, Gordon & Co., NOMAD & Broker
Andrew Burnett, Rakesh Sharma +44 20 7459 3600
Espirito Santo Investment Bank
James Bromhead, Richard Crawley +44 20 7456 9191
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDKKDNCBKDCBB
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024